To elucidate that, a series of preclinical and clinical studies are needed in order to make a therapeutic intervention, for example, administration of RANKL inhibitor, to abrogate Treg‐mediated immunosuppression at the tumor site. Here, TNFSF11 is linked to neoplasm.